Kamada (NASDAQ:KMDA) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kamada (NASDAQ:KMDA) in a research report sent to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $11.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Kamada’s Q2 2024 earnings at $0.05 EPS, Q3 2024 earnings at $0.05 EPS, FY2026 earnings at $0.57 EPS and FY2028 earnings at $0.76 EPS.

Kamada Price Performance

Shares of NASDAQ:KMDA opened at $5.53 on Thursday. The company has a market capitalization of $317.86 million, a P/E ratio of 24.07 and a beta of 1.05. The business’s 50 day simple moving average is $5.54 and its 200 day simple moving average is $5.54. Kamada has a 1 year low of $4.08 and a 1 year high of $6.53.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.04. Kamada had a return on equity of 5.50% and a net margin of 8.33%. The company had revenue of $36.43 million for the quarter, compared to analysts’ expectations of $37.71 million. On average, sell-side analysts anticipate that Kamada will post 0.23 EPS for the current fiscal year.

Institutional Trading of Kamada

Several large investors have recently made changes to their positions in KMDA. Vanguard Group Inc. raised its position in Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares in the last quarter. Calton & Associates Inc. acquired a new position in shares of Kamada during the 4th quarter worth $111,000. Aristides Capital LLC boosted its stake in Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 16,635 shares in the last quarter. Y.D. More Investments Ltd grew its position in Kamada by 107.1% in the fourth quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 15,000 shares during the last quarter. Finally, EWA LLC acquired a new position in Kamada during the fourth quarter worth about $68,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.